Laser-Induced Forward Transfer Printing on Microneedles for Transdermal Delivery of Gemcitabine

Zoi Kanaki, Chrysoula Chandrinou, Ioanna-Maria Orfanou, Christina Kryou, Jill Ziesmer, Georgios A. Sotiriou, Apostolos Klinakis, Constantin Tamvakopoulos, Ioanna Zergioti

Article ID: 554
Vol 8, Issue 2, 2022, Article identifier:

VIEWS - 329 (Abstract) 71 (PDF)



Cancer treatment with chemotherapeutic drugs remains to be challenging to the physician due to limitations associated with lack of efficacy or high toxicities. Typically, chemotherapeutic drugs are administered intravenously, leading to high drug concentrations that drive efficacy but also lead to known side effects. Delivery of drugs through transdermal microneedles (MNs) has become an important alternative treatment approach. Such delivery options are well suited for chemotherapeutic drugs in which sustained levels would be desirable. In the context of developing a novel approach, laser induced forward transfer (LIFT) was applied for bioprinting of gemcitabine (Gem) to coat polymethylmethacrylate MNs. Gem, a chemotherapeutic agent used to treat various types of cancer, is a good candidate for MN-assisted transdermal delivery to improve the pharmacokinetics of Gem while reducing efficiency limitations. LIFT bioprinting of Gem for coating of MNs with different drug amounts and successful transdermal delivery in mice is presented in this study. Our approach produced reproducible, accurate, and uniform coatings of the drug on MN arrays, and on in vivo transdermal application of the coated MNs in mice, dose-proportional concentrations of Gem in the plasma of mice was achieved. The developed approach may be extended to several chemotherapeutics and provide advantages for metronomic drug dosing.


Laser-induced forward transfer bioprinting, Microneedles, Metronomic chemotherapy, Pharmacokinetics, Transdermal dosing, Sustained drug release

Full Text:



Waghule T, Singhvi G, Dubey SK, et al., 2019, Microneedles: A Smart Approach and Increasing Potential for Transdermal Drug Delivery System. Biomed Pharmacother, 109:1249–58.

Sirbubalo M, Tucak A, Muhamedagic K, et al., 2021, 3D Printing a “Touch-Button” Approach to Manufacture Microneedles for Transdermal Drug Delivery. Pharmaceutics, 13:924.

Kochhar JS, Quek TC, Soon WJ, et al., 2013, Effect of Microneedle Geometry and Supporting Substrate on Microneedle Array Penetration into Skin. J Pharm Sci, 102:4100–8.

Larrañeta E, Moore J, Vicente-Pérez EM, et al., 2014, A Proposed Model Membrane and Test Method for Microneedle Insertion Studies. Int J Pharm, 472:65–73.

Larrañeta E, Lutton RE, Woolfson AD, et al., 2016, Microneedle Arrays as Transdermal and Intradermal Drug Delivery Systems: Materials Science, Manufacture and Commercial Development. Mater Sci Eng R Rep, 104:1–32.

Ziesmer J, Tajpara P, Hempel NJ, et al., 2021, Vancomycin-Loaded Microneedle Arrays against Methicillin-Resistant Staphylococcus Aureus Skin Infections. Adv Mater Technol, 6:2001307.

Gill HS, Prausnitz MR, 2007, Coated Microneedles for Transdermal Delivery. J Control Release, 117:227–37.

Yang Y, Kalluri H, Banga AK, 2011, Effects of Chemical and Physical Enhancement Techniques on Transdermal Delivery of Cyanocobalamin (Vitamin B12) In Vitro. Pharmaceutics, 3:474–484.

Vranic E, Tucak A, Sirbubalo J, et al., 2019, Microneedle based Sensor Systems for Real-time Continuous Transdermal Monitoring of Analytes in Body Fluids. Vol. 73. Cham, Switzerland: Proceedings of the CMBEBIH 2019, IFMBE Proceedings, Springer, p167–172.

Pearton M, Saller V, Coulman SA, et al., 2012, Microneedle Delivery of Plasmid DNA to Living Human Skin: Formulation Coating, Skin Insertion and Gene Expression. J Control Release, 160:561–9.

Zhao X, Coulman SA, Hanna SJ, et al., 2017, Formulation of Hydrophobic Peptides for Skin Delivery Via Coated Microneedles. J Control Release, 265:2–13.

Tuan-Mahmood TM, McCrudden MT, Torrisi BM, et al., 2013, Microneedles for Intradermal and Transdermal Drug Delivery. Eur J Pharm Sci, 50:623–37.

Ameri M, Kadkhodayan M, Nguyen J, et al., 2014, Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses. Pharmaceutics, 6:220–34.

Chen X, Prow TW, Crichton ML, et al., 2009, Dry-coate Microprojection Array Patches for Targeted Delivery of Immune-therapeutics to the Skin. J Control Release, 139:212–20.

Chen X, Fernando GJ, Crichton ML, et al., 2011, Improving the Reach of Vaccines to Low-resource Regions, with a Needle-free Vaccine Delivery Device and Long-term Thermostabilization. J Control Release, 152:349–55.

McGrath MG, Vrdoljak A, O’Mahony C, et al., 2011, Determination of Parameters for Successful Spray Coating of Silicon Microneedle Arrays. Int J Pharm, 415:140–9.

Vrdoljak A, McGrath MG, Carey JB, et al., 2012, Coated Microneedle Arrays for Transcutaneous Delivery of Live Virus Vaccines. J Control Release, 159:34–42.

Bierwagen GP, 1992. Film Coating Technologies and Adhesion. Electrochim Acta. 37:1471–8.

Gill HS, Prausnitz MR, 2007, Coating Formulations for Microneedles. Pharm Res, 24:1369–80.

Alhnan MA, Okwuosa TC, Sadia M, et al., 2016, Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharm Res, 33:1817.

Uddin MJ, Scoutaris N, Klepetsanis P, et al., 2015, Inkjet Printing of Transdermal Microneedles for the Delivery of Anticancer Agents. Int J Pharm, 494:593–602.

Ross S, Scoutaris N, Lamprou D, et al., 2015, Inkjet Printing of Insulin Microneedles for Transdermal Delivery. Drug Deliv Transl Res, 5:451–61.

Uddin MJ, Scoutaris N, Economidou SN, et al., 2020, 3D Printed Microneedles for Anticancer Therapy of Skin Tumours. Mater Sci Eng C Mater Biol Appl, 107:110248.

Tarbox TN, Watts AB, Cui Z, et al., 2018, An Update on Coating/Manufacturing Techniques of Microneedles. Drug Deliv Transl Res, 8:1828–43.

Haj-Ahmad R, Khan H, Arshad MS, et al., 2015, Microneedle Coating Techniques for Transdermal Drug Delivery. Pharmaceutics, 7:486–502.

Papazoglou S, Zergioti I, 2017, Laser Induced Forward Transfer (LIFT) of nano-micro patterns for sensor applications. Microelectron Eng Rev, 182:25–34.

Paroha S, Verma J, Dubey RD, et al., 2021, Recent Advances and Prospects in Gemcitabine Drug Delivery Systems. Int J Pharm, 592:120043.

Reid JM, Qu W, Safgren SL, et al., 2004. Phase I Trial and Pharmacokinetics of Gemcitabine in Children with Advanced Solid Tumors. J Clin Oncol, 22:2445–51.

Bhatnagar S, Kumari P, Pattarabhiran SP, et al., 2018, Zein Microneedles for Localized Delivery of Chemotherapeutic Agents to Treat Breast Cancer: Drug Loading, Release Behavior, and Skin Permeation Studies. AAPS PharmSciTech, 19:1818–26.

Karampelas T, Argyros O, Sayyad N, et al., 2014. GnRH Gemcitabine Conjugates for the Treatment of Androgen-independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery. Bioconjug Chem, 25:813–23. https://doi: 10.1021/bc500081g

Karampelas T, Skavatsou E, Argyros O, et al., 2017. Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. Mol Pharm, 14:674–85.

Sayyad N, Vrettos EI, Karampelas T, et al., 2019. Development of Bioactive Gemcitabine-D-Lys6-GnRH Prodrugs with Linker-controllable Drug Release Rate and Enhanced Biopharmaceutical Profile. Eur J Med Chem, 166:256–66. https://doi:10.1016/j.ejmech.2019.01.041

Skavatsou E, Semitekolou M, Morianos I, et al., 2021. Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC. Cancers (Basel), 13:1901.

Infante JR, Benhadji KA, Dy GK, et al., 2015. Phase 1b Study of the Oral Gemcitabine “Pro-drug” LY2334737 in Combination with Capecitabine in Patients with Advanced Solid Tumors. Invest New Drugs, 33:432–9.

Kanaki Z, Voutsina A, Markou A, et al., 2021, Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. Cancers (Basel), 13:2446.

Wang W, Chrisey DB, 2008, Study of Impact-Induced Mechanical Effects in Cell Direct. J Manuf Sci Eng, 130:1–10.

Theodorakos I, Kalaitzis A, Makrygianni M, et al., 2019, Laser-induced forward transfer of high viscous, nonnewtonian silver nanoparticle inks: Jet dynamics and temporal evolution of the printed droplet study. Adv Eng Mater, 21:1900605.

Makrygianni M, Millionis A, Kryou C, et al., 2018, On-Demand Laser Printing of Picoliter-Sized, Highly Viscous, Adhesive Fluids: Beyond Inkjet Limitations. Adv Mater Interfaces, 5:1800440.

Pratt SE, Durland-Busbice S, Shepard RL, et al., 2013. Efficacy of Low-dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts. Mol Cancer Ther, 12:481–90.

Veltkamp SA, Jansen RS, Callies S, et al, 2008. Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study. Clin Cancer Res, 14:3477–86.



  • There are currently no refbacks.

Copyright (c) 2022 Author(s).

License URL: